Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;60(6):1022-6.
doi: 10.1002/pbc.24427. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: central nervous system tumors

Amar Gajjar  1 , Roger J Packer, N K Foreman, Kenneth Cohen, Daphne Haas-Kogan, Thomas E Merchant; COG Brain Tumor Committee
Affiliations
Review

Children's Oncology Group's 2013 blueprint for research: central nervous system tumors

Amar Gajjar et al. Pediatr Blood Cancer. 2013 Jun.

Abstract

In the US, approximately 2,500 children are diagnosed annually with brain tumors. Their survival ranges from >90% to <10%. For children with medulloblastoma, the most common malignant brain tumor, 5-year survival ranges from >80% (standard-risk) to 60% (high-risk). For those with high-grade gliomas (HGGs) including diffuse intrinsic pontine gliomas, 5-year survival remains <10%. Sixty-five percent patients with ependymoma are cured after surgery and radiation therapy depending on the degree of resection and histopathology of the tumor. Phase II trials for brain tumors will investigate agents that act on cMET, PDGFRA, or EZH2 in HGG, DIPG, or medulloblastoma, respectively. Phase III trials will explore risk-based therapy stratification guided by molecular and clinical traits of children with medulloblastoma or ependymoma.

PubMed Disclaimer

References

    1. Gurney JG, Smith MA, Bunnin GR. Chapter III: CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program; Bethesda, MD: 1999. NIH Publication 99-4649.
    1. Gottardo NG, Gajjar A. Current therapy for medulloblastoma. Curr Treat Options Neurol. 2006;8:319–334. - PubMed
    1. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer. 2002;94:552–560. - PubMed
    1. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2010;29:1408–1414. - PMC - PubMed
    1. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–1931. - PubMed

Substances